Sector News

Stada's first real bidder has put up a $3.7B offer

February 23, 2017
Life sciences

When the week began, Stada had plenty of interested suitors hanging around, but it wasn’t sure any of them would turn up with a real offer. Now, the first has come in—and whether that offer will trigger a bidding war is anyone’s guess.

On Thursday, the German drugmaker announced that Boston private equity outfit Advent International had put up a legally binding bid of €58 per share in cash, plus a 2016 dividend payment; in 2015, that payment amounted to €0.70 per share, Stada noted.

Stada made clear that it’s plenty interested in other offers, however. The company said its board will go over the proposal and continue its “open-minded talks with all interested parties to evaluate further value-enhancing potential, the value of strategic concepts, and to secure the interests of all stakeholders.”

Those other interested parties include Advent’s fellow private equity firm Cinven, based in London, and one unnamed third player that entered the fray late last week. Bernstein analyst Ronny Gal has surmised that the mystery third bidder could be generics giant Mylan, which is looking to expand in Europe and could handle swallowing a $3.7 billion deal.

“We can’t see a major reason why Mylan is not the third bidder,” he recently wrote to clients.

Stada may well draw others into the picture, too. Last summer, when the company was said to be exploring a sale as part of a mission to fend off activist investors, it reportedly fielded interest from multiple private equity firms, including Luxembourg’s CVC Capital Partners.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.